Table 4 Published frontline trials of TKI-based regimens in adult Ph-positive ALL
TKI | N | Median age, years [range] | CR rate, % | Induction mortality, % | Overall CMR rate, % | HSCT rate, % | RFS rate, % | OS rate, % | Reference |
|---|---|---|---|---|---|---|---|---|---|
Intensive chemotherapy + TKI | |||||||||
 Imatinib | 54 | 51 [17-84] | 93 | 2 | 45 | 30 | 43 (5-year) | 43 (5-year) | [10] |
 Imatinib | 169 | 42 [16-64] | 92 | 5 | NR | 72 | 50 (4-year) | 38 (4-year) | [53] |
 Dasatinib | 72 | 55 [21-80] | 96 | 4 | 60 | 17 | 44 (5-year) | 46 (5-year) | [54] |
 Nilotinib | 90 | 47 [17-71] | 91 | 9 | 86 | 70 | 72 (2-year) | 72 (2-year) | [55] |
 Ponatinib | 86 | 46 [21-80] | 100 | 0 | 86 | 21 | 84 (3-year) | 78 (3-year) | |
Lower-intensity chemotherapy + TKI | |||||||||
 Imatinib | 135 | 49 [18-59] | 98 | 9 | 28 | 62 | EFS 37 (5-year) | 46 (5-year) | [11] |
 Dasatinib | 71 | 69 [59-83] | 96 | 4 | 24 | 10 | EFS 28 (5-year) | 36 (5-year) | [58] |
 Dasatinib | 60 | 42 [19-60] | 100 | 0 | 19 | 42 | 49 (3-year) | 58 (3-year) | [59] |
 Nilotinib | 79 | 65 [55-85] | 94 | 2 | 58 | 16 | 42 (4-year) | 47 (4-year) | [60] |
 Nilotinib | 60 | 47 [18-59] | 98 | 2 | NR; MMR 80 | 52 | 85 (1-year) | 96 (1-year) | [61] |
Steroids + TKI | |||||||||
 Imatinib | 30 | 69 [61-83] | 100 | 0 | 4 | NR | 48 (1-year) | 74 (1-year) | [62] |
 Dasatinib | 53 | 54 [24-77] | 100 | 0 | 15 | 34 | 51 (2-year) | 69 (2-year) | [63] |
 Ponatinib | 42 | 69 [27-85] | 95 | 0 | 46 | NR | NR | 88 (1-year) | [64] |
Blinatumomab + TKI | |||||||||
 Dasatinib | 63 | 55 [24-82] | 97 | 2 | 36 | 19 | 88 (1-year) | 95 (1-year) | [65] |